Next 10 |
2024-03-18 11:30:02 ET Wedbush analyst issues BUY recommendation for RARE on March 18, 2024 09:00AM ET. The previous analyst recommendation was Buy. RARE was trading at $47.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
2024-03-11 11:53:40 ET Summary Positive interim results released from phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy. Functional and strength data from the phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients...
2024-03-09 09:55:42 ET Summary Ultragenyx's stock has increased by approximately 9% but lags behind the S&P's return of 28%. The article assesses Ultragenyx's current merits per its recently reported Q4, 2023 earnings as we progress into 2024. The previous "Sell" rating ba...
2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...
44 th Annual Cowen Healthcare Conference on March 4 Leerink Partners Global Biopharma Conference on March 12 Barclays 26 th Annual Global Healthcare Conference on March 13 NOVATO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceut...
2024-02-23 01:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-15 23:55:23 ET Call End: Ultragenyx Pharmaceutical, Inc. (RARE) Q4 2023 Earnings Conference Call February 15, 2024, 05:00 PM ET Company Participants Joshua Higa - Vice President of Investor Relations Emil Kakkis - Chief Executive Officer & President ...
2024-02-15 16:02:14 ET More on Ultragenyx Pharmaceutical A Deeper Look At Ultragenyx Pharmaceutical DOJ says Ultragenyx to pay $6M to resolve Medicare claims allegations Wells Fargo starts Ultragenyx coverage with overweight rating Seeking Alpha’s Quan...
2023 Total Revenue of $434 million, Crysvita® revenue of $328 million and Dojolvi® revenue of $71 million 2024 Financial Guidance: Total Revenue between $500 million and $530 million, Crysvita revenue of $375 million to $400 million, and Dojolvi revenue of $75 million to $80 m...
2024-02-15 11:30:02 ET Wells Fargo analyst issues OUTPERFORM recommendation for RARE on February 15, 2024 11:00AM ET. The previous analyst recommendation was Outperform. RARE was trading at $46.41 at issue of the analyst recommendation. The overall analyst consensus : BU...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
2024-03-18 11:30:02 ET Wedbush analyst issues BUY recommendation for RARE on March 18, 2024 09:00AM ET. The previous analyst recommendation was Buy. RARE was trading at $47.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
44th Annual Cowen Healthcare Conference on March 4 Leerink Partners Global Biopharma Conference on March 12 Barclays 26th Annual Global Healthcare...
44 th Annual Cowen Healthcare Conference on March 4 Leerink Partners Global Biopharma Conference on March 12 Barclays 26 th Annual Global Healthcare Conference on March 13 NOVATO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceut...